Cancer vaccine shows early promise in clinical trial
Filed with ASX · · 2 pages · English
Earlier from Imugene
- Business Update - December Quarter Appendix 4C
- Rights Issue Results & Shortfall Notification
- Imugene raises $8.7 million
- Response to ASX Price Query
- IMU Receives $1.1m R&D Tax Refund
Later from Imugene
- IMU Meets Investigator for Gastric Cancer Clinical Trial
- Novel Anti-PD-1 Mimotope Vaccine Ready for Development
- Arginine Modulator Active in Cancer Models
- Leslie Chong Appointed as Managing Director
- Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene